UBS initiated coverage of Rohto Pharmaceutical (RPHCF) with a Neutral rating and 2,600 yen price target The firm sees a balanced risk/reward at the stock’s current valuation, noting the company’s core business growth has slowed.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF:
- Rohto Pharmaceutical Reports Strong Growth in Latest Earnings
- Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan
- Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward
- Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion
- Rohto Pharmaceutical’s New Study: A Potential Game-Changer for Heart Disease Treatment?